Motilal Oswal: Indian Pharma Market Declines In August After Posting Muted Growth In July 2020
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
The Indian Pharma market (IPM) declined by 2.2% YoY in August 2020 (versus muted growth of 0.2% YoY in July 2020).
The volume decline of 9.2% YoY dragged the IPM’s performance, which was offset by growth in 1. prices by 4.4% YoY, and 2. new launches by 2.5% YoY to some extent.
Therapy-wise in August 2020, anti-infective/respiratory/anti-malaria declined 11%/12.4%/19.6% YoY, while cardiac/vitamins, minerals and nutrients/anti-diabetic grew 11.5%/6.2%/1.6% YoY.
For the quarter ending August 2020, the IPM’s growth was subdued at 0.2%YoY.
Volumes declined 6.6% YoY, prices grew 4.6% YoY and growth in new products was up 2.2% YoY.
National list of essential medicines (NLEM) products grew 0.8% YoY while growth in Non-NLEM products were muted YoY.
On moving annual total basis, industry growth came in at 4.1% YoY.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.